ATE536886T1 - Stabilisierte feste zusammensetzungen von modifizierter faktor vii - Google Patents

Stabilisierte feste zusammensetzungen von modifizierter faktor vii

Info

Publication number
ATE536886T1
ATE536886T1 AT03720286T AT03720286T ATE536886T1 AT E536886 T1 ATE536886 T1 AT E536886T1 AT 03720286 T AT03720286 T AT 03720286T AT 03720286 T AT03720286 T AT 03720286T AT E536886 T1 ATE536886 T1 AT E536886T1
Authority
AT
Austria
Prior art keywords
factor vii
modified factor
solid compositions
stabilized solid
composition
Prior art date
Application number
AT03720286T
Other languages
English (en)
Inventor
Hanne Nedergaard
Lars Hansen
Niels Klausen
Troels Kornfelt
James Flink
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE536886T1 publication Critical patent/ATE536886T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Ceramic Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03720286T 2002-05-03 2003-05-02 Stabilisierte feste zusammensetzungen von modifizierter faktor vii ATE536886T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200677 2002-05-03
PCT/DK2003/000287 WO2003092731A1 (en) 2002-05-03 2003-05-02 Stabilised solid compositions of modified factor vii

Publications (1)

Publication Number Publication Date
ATE536886T1 true ATE536886T1 (de) 2011-12-15

Family

ID=29286050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03720286T ATE536886T1 (de) 2002-05-03 2003-05-02 Stabilisierte feste zusammensetzungen von modifizierter faktor vii

Country Status (6)

Country Link
EP (1) EP1503798B8 (de)
JP (1) JP5184738B2 (de)
AT (1) ATE536886T1 (de)
AU (1) AU2003223925A1 (de)
ES (1) ES2377959T3 (de)
WO (1) WO2003092731A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002350115A1 (en) 2001-11-01 2003-05-12 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
EP1458408B1 (de) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Flüssige zusammensetzung aus faktor vii polypeptiden
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
CN101818137A (zh) * 2003-03-18 2010-09-01 诺和诺德医疗保健公司 生产含有gla残基的丝氨酸蛋白酶的方法
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1641487B1 (de) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Flüssige zusammensetzungen von factor vii polypeptiden
CN1917861B (zh) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
AU2011203354B2 (en) * 2003-12-19 2014-07-17 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
CN1913917B (zh) * 2003-12-31 2012-02-01 正统逻辑公司 凝血酶肽衍生物的药物组合物
WO2007010995A1 (ja) * 2005-07-20 2007-01-25 Kyowa Medex Co., Ltd. 生体試料中のペプチドの安定化方法
RU2396953C2 (ru) * 2006-02-09 2010-08-20 Спектрум Фармасьютикалз, Инк. Лечение рака мочевого пузыря с использованием ео9 и пропиленгликоля
US11077193B2 (en) 2015-04-21 2021-08-03 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
KR102605317B1 (ko) 2016-10-07 2023-11-24 리제너론 파아마슈티컬스, 인크. 실온 안정성 동결건조된 단백질

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
WO1992015686A1 (en) * 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
DE60009926T2 (de) * 1999-08-17 2005-04-07 Novo Nordisk Health Care Ag Stabilisierung von gefriergetrocknetem kuchen
EP1280548B1 (de) * 2000-05-03 2013-12-11 Novo Nordisk Health Care AG Subkutane Verabreichung des Koagulationsfaktor VII

Also Published As

Publication number Publication date
EP1503798A1 (de) 2005-02-09
ES2377959T3 (es) 2012-04-03
EP1503798B8 (de) 2012-03-14
JP5184738B2 (ja) 2013-04-17
EP1503798B1 (de) 2011-12-14
AU2003223925A1 (en) 2003-11-17
WO2003092731A1 (en) 2003-11-13
JP2005530752A (ja) 2005-10-13

Similar Documents

Publication Publication Date Title
ATE536886T1 (de) Stabilisierte feste zusammensetzungen von modifizierter faktor vii
DE69932645D1 (de) Neue Fettsäureanaloge zur Behandlung der Fettleber
ATE428439T1 (de) Flüssige zusammensetzung aus faktor vii polypeptiden
NO20034291D0 (no) 2-aminopropanolderivater
FI952610A7 (fi) Stabiloituja, nestemäisiä entsyymikoostumuksia
DE60217844D1 (de) Trocknungszusammensetzung
ATE172490T1 (de) Kalzium xylolsulfonat enthaltende, konzentrierte flüssige oder gelförmige geschirrspülmittelzusammensetzungen
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
GB0101403D0 (en) Improvements in or relating to organic compositions
DE60115922D1 (de) Verfahren zur verzögerung der abbaugeschwindigkeit von bioabbaubarem polymer und bioabbaubare polymerzusammensetzungen
DE60000616D1 (de) Mineralwasser enthaltende Zusammensetzungen
EE9900022A (et) Värvuskompositsioon, mis koosneb pürogalloolstruktuure sisaldavast agendist, raud(II)soolast ning orgaanilisest happest
MY147790A (en) Stable emulsion composition
TR200401573T4 (tr) Stabilize edilmiş granülosit koloni uyarıcı faktör
DE69917245T2 (de) Betablocker enthaltende ophtalmische zusammensetzungen
TR200201392T2 (tr) Su ıslah maddesi
BRPI0411664A (pt) composição oral antiplaca aquosa estável
EE200200262A (et) Väetiselisand, mis sisaldab magneesium- ja kaltsiumsulfaati ja -karbonaati
GB2387101A (en) Compositions containing creatine and creatinine
BR0214590A (pt) composições lìquidas de leveduras
DE60219462D1 (de) Verdickte wässrige zusammensetzungen
ATE205386T1 (de) Einphasige,transparente wässrige zusammensetzung
DK0651614T3 (da) Stabiliseret fødevaresammensætning
MXPA03005653A (es) Composicion liquida coloreada para marcador de textos.
RU2001116708A (ru) Состав для обработки призабойной зоны пласта